CONTROLLED SUB-XYLAZINE

Illinois General Assembly - Full Text of SB3221

Select Language

×

The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.

Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.

The English language version is always the official and authoritative version of this website.

NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.

Choose Language

English

Afrikaans

Albanian

Arabic

Armenian

Azerbaijani

Basque

Bengali

Bosnian

Catalan

Croatian

Czech

Danish

Dutch

Esperanto

Estonian

Filipino

Finnish

French

Galician

Georgian

German

Greek

Gujarati

Haitian Creole

Hausa

Hawaiian

Hebrew

Hindi

Hungarian

Icelandic

Indonesian

Interlingua

Interlingue

Inuktitut

Irish

Italian

Japanese

Javanese

Kannada

Khmer

Korean

Latin

Latvian

Lithuanian

Luxembourgish

Macedonian

Malagasy

Malayalam

Maltese

Maori

Marathi

Myanmar

Nepali

Norwegian

Odia

Pashto

Punjabi

Romanian

Russian

Samoan

Sango

Sanskrit

Sardinian

Sindhi

Sinhala

Slovak

Slovenian

Somali

Southern Sotho

Spanish

Sundanese

Swahili

Swedish

Tamil

Telugu

Thai

Tigrinya

Tonga

Turkish

Ukrainian

Urdu

Vietnamese

Welsh

Xhosa

Yiddish

Yoruba

Zulu

Powered by
Translate

Close

Illinois General Assembly

Top Navigation Bar

Translate

Learn

Select General Assembly

Search the 104th General Assembly

Enter search terms for legislation, members, committees, or schedules.

ILGA.GOV

LEGISLATION & LAWS

Bills & Resolutions

Public Acts

Illinois Compiled Statutes

Illinois Constitution

Search Legislation

Glossary

Guide

Reports & Inquiry

Legislative Reports

Special Reports

FTP Site

Legislator Lookup

Capitol Complex Phone Numbers

Rules & Regulations

Illinois Register

Administrative Rules

Senate

Members

Schedules

Committees

Request for Remote Testimony

Journals

Transcripts

Rules

Audio/Video

FOIA Information

Senate Employment Opportunities

Media Guidelines

House

Members

Schedules

Committees

Submit testimony for House Committees

Journals

Transcripts

Rules

Audio/Video

FOIA Information

House Employment Opportunities

Log In

Mobile Top Bar

Search the 104th General Assembly

Enter keywords to search the Illinois General Assembly website.

Full Text of SB3221

Home

Legislation

Full Text

SB3221 - 104th General Assembly

Bill Status

Full Text

Votes

Witness Slips

Select Menu

Bill Status

Full Text

Votes

Witness Slips

Printer Friendly Version

Introduced

Printer Friendly Version

Introduced

Open PDF

104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026
SB3221

Introduced 2/2/2026, by Sen. Julie A. Morrison

SYNOPSIS AS INTRODUCED:

720 ILCS 570/102

from Ch. 56 1/2, par. 1102
720 ILCS 570/204

from Ch. 56 1/2, par. 1204
720 ILCS 570/206

from Ch. 56 1/2, par. 1206
720 ILCS 570/208

from Ch. 56 1/2, par. 1208
720 ILCS 570/309.1 new

Amends the Illinois Controlled Substances Act. Makes structural and
other changes to the list of controlled substances. Adds xylazine as a
Class III controlled substance. Provides that notwithstanding the
scheduling of xylazine as a Schedule III controlled substance, xylazine
shall not be considered a controlled substance when: (1) used by licensed
Illinois veterinarians dispensing or prescribing for, or administering to,
a nonhuman species of a drug containing xylazine that has been approved by
the U.S. Food and Drug Administration; (2) used by licensed Illinois
veterinarians dispensing or prescribing for, or administering to, a
nonhuman species that is permissible under the Federal Food, Drug, and
Cosmetic Act; (3) manufactured, distributed, or used as an active
pharmaceutical ingredient for manufacturing an animal drug approved under
the Federal Food, Drug, and Cosmetic Act; (4) used by a licensed certified
euthanasia technician employed by a certified euthanasia agency; or (5)
used by a wildlife biologist engaged in legal or authorized fieldwork
under the indirect supervision of a veterinarian. Defines "isomer".
Effective January 1, 2027.
LRB104 20204 RLC 33655 b

A BILL FOR

SB3221
LRB104 20204 RLC 33655 b
1

AN ACT concerning criminal law.

2

Be it enacted by the People of the State of Illinois,
3
represented in the General Assembly:

4

Section 5.
The Illinois Controlled Substances Act is
5
amended by changing Sections 102, 204, 206, and 208 and by
6
adding Section 309.1 as follows:

7

(720 ILCS 570/102)

(from Ch. 56 1/2, par. 1102)
8

Sec. 102.
Definitions.
As used in this Act, unless the
9
context otherwise requires:
10

(a) "Person with a substance use disorder" means any
11
person who has a substance use disorder diagnosis defined as a
12
spectrum of persistent and recurring problematic behavior that
13
encompasses 10 separate classes of drugs: alcohol; caffeine;
14
cannabis; hallucinogens; inhalants; opioids; sedatives,
15
hypnotics and anxiolytics; stimulants; and tobacco; and other
16
unknown substances leading to clinically significant
17
impairment or distress.
18

(b) "Administer" means the direct application of a
19
controlled substance, whether by injection, inhalation,
20
ingestion, or any other means, to the body of a patient,
21
research subject, or animal (as defined by the Humane
22
Euthanasia in Animal Shelters Act) by:
23

(1) a practitioner (or, in his or her presence, by his

SB3221
- 2 -
LRB104 20204 RLC 33655 b
1

or her authorized agent),
2

(2) the patient or research subject pursuant to an
3

order, or
4

(3) a euthanasia technician as defined by the Humane
5

Euthanasia in Animal Shelters Act.
6

(c) "Agent" means an authorized person who acts on behalf
7
of or at the direction of a manufacturer, distributor,
8
dispenser, prescriber, or practitioner. It does not include a
9
common or contract carrier, public warehouseman or employee of
10
the carrier or warehouseman.
11

(c-1) "Anabolic Steroids" means any drug or hormonal
12
substance, chemically and pharmacologically related to
13
testosterone (other than estrogens, progestins,
14
corticosteroids, and dehydroepiandrosterone), and includes:
15

(i) 3[beta],17-dihydroxy-5a-androstane,
16

(ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
17

(iii) 5[alpha]-androstan-3,17-dione,
18

(iv) 1-androstenediol (3[beta],
19

17[beta]-dihydroxy-5[alpha]-androst-1-ene),
20

(v) 1-androstenediol (3[alpha],
21

17[beta]-dihydroxy-5[alpha]-androst-1-ene),
22

(vi) 4-androstenediol
23

(3[beta],17[beta]-dihydroxy-androst-4-ene),
24

(vii) 5-androstenediol
25

(3[beta],17[beta]-dihydroxy-androst-5-ene),
26

(viii) 1-androstenedione

SB3221
- 3 -
LRB104 20204 RLC 33655 b
1

([5alpha]-androst-1-en-3,17-dione),
2

(ix) 4-androstenedione
3

(androst-4-en-3,17-dione),
4

(x) 5-androstenedione
5

(androst-5-en-3,17-dione),
6

(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
7

hydroxyandrost-4-en-3-one),
8

(xii) boldenone (17[beta]-hydroxyandrost-
9

1,4,-diene-3-one),
10

(xiii) boldione (androsta-1,4-
11

diene-3,17-dione),
12

(xiv) calusterone (7[beta],17[alpha]-dimethyl-17
13

[beta]-hydroxyandrost-4-en-3-one),
14

(xv) clostebol (4-chloro-17[beta]-
15

hydroxyandrost-4-en-3-one),
16

(xvi) dehydrochloromethyltestosterone (4-chloro-
17

17[beta]-hydroxy-17[alpha]-methyl-
18

androst-1,4-dien-3-one),
19

(xvii) desoxymethyltestosterone
20

(17[alpha]-methyl-5[alpha]
21

-androst-2-en-17[beta]-ol)(a.k.a., madol),
22

(xviii) [delta]1-dihydrotestosterone (a.k.a.
23

'1-testosterone') (17[beta]-hydroxy-
24

5[alpha]-androst-1-en-3-one),
25

(xix) 4-dihydrotestosterone (17[beta]-hydroxy-
26

androstan-3-one),

SB3221
- 4 -
LRB104 20204 RLC 33655 b
1

(xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
2

5[alpha]-androstan-3-one),
3

(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
4

hydroxyestr-4-ene),
5

(xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
6

1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
7

(xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
8

17[beta]-dihydroxyandrost-1,4-dien-3-one),
9

(xxiv) furazabol (17[alpha]-methyl-17[beta]-
10

hydroxyandrostano[2,3-c]-furazan),
11

(xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
12

(xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
13

androst-4-en-3-one),
14

(xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
15

dihydroxy-estr-4-en-3-one),
16

(xxviii) mestanolone (17[alpha]-methyl-17[beta]-
17

hydroxy-5-androstan-3-one),
18

(xxix) mesterolone (1amethyl-17[beta]-hydroxy-
19

[5a]-androstan-3-one),
20

(xxx) methandienone (17[alpha]-methyl-17[beta]-
21

hydroxyandrost-1,4-dien-3-one),
22

(xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
23

dihydroxyandrost-5-ene),
24

(xxxii) methenolone (1-methyl-17[beta]-hydroxy-
25

5[alpha]-androst-1-en-3-one),
26

(xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-

SB3221
- 5 -
LRB104 20204 RLC 33655 b
1

dihydroxy-5a-androstane,
2

(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
3

-5a-androstane,
4

(xxxv) 17[alpha]-methyl-3[beta],17[beta]-
5

dihydroxyandrost-4-ene),
6

(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
7

methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
8

(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
9

hydroxyestra-4,9(10)-dien-3-one),
10

(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
11

hydroxyestra-4,9-11-trien-3-one),
12

(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
13

hydroxyandrost-4-en-3-one),
14

(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
15

hydroxyestr-4-en-3-one),
16

(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
17

(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
18

androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl-
19

1-testosterone'),
20

(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
21

(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
22

dihydroxyestr-4-ene),
23

(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
24

dihydroxyestr-4-ene),
25

(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
26

dihydroxyestr-5-ene),

SB3221
- 6 -
LRB104 20204 RLC 33655 b
1

(xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
2

dihydroxyestr-5-ene),
3

(xlvii) 19-nor-4,9(10)-androstadienedione
4

(estra-4,9(10)-diene-3,17-dione),
5

(xlviii) 19-nor-4-androstenedione (estr-4-
6

en-3,17-dione),
7

(xlix) 19-nor-5-androstenedione (estr-5-
8

en-3,17-dione),
9

(l) norbolethone (13[beta], 17a-diethyl-17[beta]-
10

hydroxygon-4-en-3-one),
11

(li) norclostebol (4-chloro-17[beta]-
12

hydroxyestr-4-en-3-one),
13

(lii) norethandrolone (17[alpha]-ethyl-17[beta]-
14

hydroxyestr-4-en-3-one),
15

(liii) normethandrolone (17[alpha]-methyl-17[beta]-
16

hydroxyestr-4-en-3-one),
17

(liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
18

2-oxa-5[alpha]-androstan-3-one),
19

(lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
20

dihydroxyandrost-4-en-3-one),
21

(lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
22

17[beta]-hydroxy-(5[alpha]-androstan-3-one),
23

(lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
24

(5[alpha]-androst-2-eno[3,2-c]-pyrazole),
25

(lviii) stenbolone (17[beta]-hydroxy-2-methyl-
26

(5[alpha]-androst-1-en-3-one),

SB3221
- 7 -
LRB104 20204 RLC 33655 b
1

(lix) testolactone (13-hydroxy-3-oxo-13,17-
2

secoandrosta-1,4-dien-17-oic
3

acid lactone),
4

(lx) testosterone (17[beta]-hydroxyandrost-
5

4-en-3-one),
6

(lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
7

diethyl-17[beta]-hydroxygon-
8

4,9,11-trien-3-one),
9

(lxii) trenbolone (17[beta]-hydroxyestr-4,9,
10

11-trien-3-one).
11

Any person who is otherwise lawfully in possession of an
12
anabolic steroid, or who otherwise lawfully manufactures,
13
distributes, dispenses, delivers, or possesses with intent to
14
deliver an anabolic steroid, which anabolic steroid is
15
expressly intended for and lawfully allowed to be administered
16
through implants to livestock or other nonhuman species, and
17
which is approved by the Secretary of Health and Human
18
Services for such administration, and which the person intends
19
to administer or have administered through such implants,
20
shall not be considered to be in unauthorized possession or to
21
unlawfully manufacture, distribute, dispense, deliver, or
22
possess with intent to deliver such anabolic steroid for
23
purposes of this Act.
24

(d) "Administration" means the Drug Enforcement
25
Administration, United States Department of Justice, or its
26
successor agency.

SB3221
- 8 -
LRB104 20204 RLC 33655 b
1

(d-5) "Clinical Director, Prescription Monitoring Program"
2
means a Department of Human Services administrative employee
3
licensed to either prescribe or dispense controlled substances
4
who shall run the clinical aspects of the Department of Human
5
Services Prescription Monitoring Program and its Prescription
6
Information Library.
7

(d-10) "Compounding" means the preparation and mixing of
8
components, excluding flavorings, (1) as the result of a
9
prescriber's prescription drug order or initiative based on
10
the prescriber-patient-pharmacist relationship in the course
11
of professional practice or (2) for the purpose of, or
12
incident to, research, teaching, or chemical analysis and not
13
for sale or dispensing. "Compounding" includes the preparation
14
of drugs or devices in anticipation of receiving prescription
15
drug orders based on routine, regularly observed dispensing
16
patterns. Commercially available products may be compounded
17
for dispensing to individual patients only if both of the
18
following conditions are met: (i) the commercial product is
19
not reasonably available from normal distribution channels in
20
a timely manner to meet the patient's needs and (ii) the
21
prescribing practitioner has requested that the drug be
22
compounded.
23

(e) "Control" means to add a drug or other substance, or
24
immediate precursor, to a Schedule whether by transfer from
25
another Schedule or otherwise.
26

(f) "Controlled Substance" means (i) a drug, substance,

SB3221
- 9 -
LRB104 20204 RLC 33655 b
1
immediate precursor, or synthetic drug in the Schedules of
2
Article II of this Act or (ii) a drug or other substance, or
3
immediate precursor, designated as a controlled substance by
4
the Department through administrative rule. The term does not
5
include distilled spirits, wine, malt beverages, or tobacco,
6
as those terms are defined or used in the Liquor Control Act of
7
1934 and the Tobacco Products Tax Act of 1995.
8

(f-5) "Controlled substance analog" means a substance:
9

(1) the chemical structure of which is substantially
10

similar to the chemical structure of a controlled
11

substance in Schedule I or II;
12

(2) which has a stimulant, depressant, or
13

hallucinogenic effect on the central nervous system that
14

is substantially similar to or greater than the stimulant,
15

depressant, or hallucinogenic effect on the central
16

nervous system of a controlled substance in Schedule I or
17

II; or
18

(3) with respect to a particular person, which such
19

person represents or intends to have a stimulant,
20

depressant, or hallucinogenic effect on the central
21

nervous system that is substantially similar to or greater
22

than the stimulant, depressant, or hallucinogenic effect
23

on the central nervous system of a controlled substance in
24

Schedule I or II.
25

(g) "Counterfeit substance" means a controlled substance,
26
which, or the container or labeling of which, without

SB3221
- 10 -
LRB104 20204 RLC 33655 b
1
authorization bears the trademark, trade name, or other
2
identifying mark, imprint, number or device, or any likeness
3
thereof, of a manufacturer, distributor, or dispenser other
4
than the person who in fact manufactured, distributed, or
5
dispensed the substance.
6

(h) "Deliver" or "delivery" means the actual, constructive
7
or attempted transfer of possession of a controlled substance,
8
with or without consideration, whether or not there is an
9
agency relationship. "Deliver" or "delivery" does not include
10
the donation of drugs to the extent permitted under the
11
Illinois Drug Reuse Opportunity Program Act.
12

(i) "Department" means the Illinois Department of Human
13
Services (as successor to the Department of Alcoholism and
14
Substance Abuse) or its successor agency.
15

(j) (Blank).
16

(k) "Department of Corrections" means the Department of
17
Corrections of the State of Illinois or its successor agency.
18

(l) "Department of Financial and Professional Regulation"
19
means the Department of Financial and Professional Regulation
20
of the State of Illinois or its successor agency.
21

(m) "Depressant" means any drug that (i) causes an overall
22
depression of central nervous system functions, (ii) causes
23
impaired consciousness and awareness, and (iii) can be
24
habit-forming or lead to a substance misuse or substance use
25
disorder, including, but not limited to, alcohol, cannabis and
26
its active principles and their analogs, benzodiazepines and

SB3221
- 11 -
LRB104 20204 RLC 33655 b
1
their analogs, barbiturates and their analogs, opioids
2
(natural and synthetic) and their analogs, and chloral hydrate
3
and similar sedative hypnotics.
4

(n) (Blank).
5

(o) "Director" means the Director of the Illinois State
6
Police or his or her designated agents.
7

(p) "Dispense" means to deliver a controlled substance to
8
an ultimate user or research subject by or pursuant to the
9
lawful order of a prescriber, including the prescribing,
10
administering, packaging, labeling, or compounding necessary
11
to prepare the substance for that delivery.
12

(q) "Dispenser" means a practitioner who dispenses.
13

(r) "Distribute" means to deliver, other than by
14
administering or dispensing, a controlled substance.
15

(s) "Distributor" means a person who distributes.
16

(t) "Drug" means (1) substances recognized as drugs in the
17
official United States Pharmacopoeia, Official Homeopathic
18
Pharmacopoeia of the United States, or official National
19
Formulary, or any supplement to any of them; (2) substances
20
intended for use in diagnosis, cure, mitigation, treatment, or
21
prevention of disease in man or animals; (3) substances (other
22
than food) intended to affect the structure of any function of
23
the body of man or animals and (4) substances intended for use
24
as a component of any article specified in clause (1), (2), or
25
(3) of this subsection. It does not include devices or their
26
components, parts, or accessories.

SB3221
- 12 -
LRB104 20204 RLC 33655 b
1

(t-3) "Electronic health record" or "EHR" means an
2
electronic record of health-related information on an
3
individual that is created, gathered, managed, and consulted
4
by authorized health care clinicians and staff.
5

(t-3.5) "Electronic health record system" or "EHR system"
6
means any computer-based system or combination of federally
7
certified Health IT Modules (defined at 42 CFR 170.102 or its
8
successor) used as a repository for electronic health records
9
and accessed or updated by a prescriber or authorized
10
surrogate in the ordinary course of his or her medical
11
practice. For purposes of connecting to the Prescription
12
Information Library maintained by the Bureau of Pharmacy and
13
Clinical Support Systems or its successor, an EHR system may
14
connect to the Prescription Information Library directly or
15
through all or part of a computer program or system that is a
16
federally certified Health IT Module maintained by a third
17
party and used by the EHR system to secure access to the
18
database.
19

(t-4) "Emergency medical services personnel" has the
20
meaning ascribed to it in the Emergency Medical Services (EMS)
21
Systems Act.
22

(t-5) "Euthanasia agency" means an entity certified by the
23
Department of Financial and Professional Regulation for the
24
purpose of animal euthanasia that holds an animal control
25
facility license or animal shelter license under the Animal
26
Welfare Act. A euthanasia agency is authorized to purchase,

SB3221
- 13 -
LRB104 20204 RLC 33655 b
1
store, possess, and utilize Schedule II nonnarcotic and
2
Schedule III nonnarcotic drugs for the sole purpose of animal
3
euthanasia.
4

(t-10) "Euthanasia drugs" means Schedule II or Schedule
5
III substances (nonnarcotic controlled substances) that are
6
used by a euthanasia agency for the purpose of animal
7
euthanasia.
8

(u) "Good faith" means the prescribing or dispensing of a
9
controlled substance by a practitioner in the regular course
10
of professional treatment to or for any person who is under his
11
or her treatment for a pathology or condition other than that
12
individual's physical or psychological dependence upon a
13
controlled substance, except as provided herein: and
14
application of the term to a pharmacist shall mean the
15
dispensing of a controlled substance pursuant to the
16
prescriber's order which in the professional judgment of the
17
pharmacist is lawful. The pharmacist shall be guided by
18
accepted professional standards, including, but not limited
19
to, the following, in making the judgment:
20

(1) lack of consistency of prescriber-patient
21

relationship,
22

(2) frequency of prescriptions for same drug by one
23

prescriber for large numbers of patients,
24

(3) quantities beyond those normally prescribed,
25

(4) unusual dosages (recognizing that there may be
26

clinical circumstances where more or less than the usual

SB3221
- 14 -
LRB104 20204 RLC 33655 b
1

dose may be used legitimately),
2

(5) unusual geographic distances between patient,
3

pharmacist and prescriber,
4

(6) consistent prescribing of habit-forming drugs.
5

(u-0.5) "Hallucinogen" means a drug that causes markedly
6
altered sensory perception leading to hallucinations of any
7
type.
8

(u-1) "Home infusion services" means services provided by
9
a pharmacy in compounding solutions for direct administration
10
to a patient in a private residence, long-term care facility,
11
or hospice setting by means of parenteral, intravenous,
12
intramuscular, subcutaneous, or intraspinal infusion.
13

(u-5) "Illinois State Police" means the Illinois State
14
Police or its successor agency.
15

(v) "Immediate precursor" means a substance:
16

(1) which the Department has found to be and by rule
17

designated as being a principal compound used, or produced
18

primarily for use, in the manufacture of a controlled
19

substance;
20

(2) which is an immediate chemical intermediary used
21

or likely to be used in the manufacture of such controlled
22

substance; and
23

(3) the control of which is necessary to prevent,
24

curtail or limit the manufacture of such controlled
25

substance.
26

(w) "Instructional activities" means the acts of teaching,

SB3221
- 15 -
LRB104 20204 RLC 33655 b
1
educating or instructing by practitioners using controlled
2
substances within educational facilities approved by the State
3
Board of Education or its successor agency.
4

(w-1) "Isomer" means optical isomer, unless specifically
5
detailed in this Act.

6

(x) "Local authorities" means a duly organized State,
7
County or Municipal peace unit or police force.
8

(y) "Look-alike substance" means a substance, other than a
9
controlled substance which (1) by overall dosage unit
10
appearance, including shape, color, size, markings or lack
11
thereof, taste, consistency, or any other identifying physical
12
characteristic of the substance, would lead a reasonable
13
person to believe that the substance is a controlled
14
substance, or (2) is expressly or impliedly represented to be
15
a controlled substance or is distributed under circumstances
16
which would lead a reasonable person to believe that the
17
substance is a controlled substance. For the purpose of
18
determining whether the representations made or the
19
circumstances of the distribution would lead a reasonable
20
person to believe the substance to be a controlled substance
21
under this clause (2) of subsection (y), the court or other
22
authority may consider the following factors in addition to
23
any other factor that may be relevant:
24

(a) statements made by the owner or person in control
25

of the substance concerning its nature, use or effect;
26

(b) statements made to the buyer or recipient that the

SB3221
- 16 -
LRB104 20204 RLC 33655 b
1

substance may be resold for profit;
2

(c) whether the substance is packaged in a manner
3

normally used for the illegal distribution of controlled
4

substances;
5

(d) whether the distribution or attempted distribution
6

included an exchange of or demand for money or other
7

property as consideration, and whether the amount of the
8

consideration was substantially greater than the
9

reasonable retail market value of the substance.
10

Clause (1) of this subsection (y) shall not apply to a
11
noncontrolled substance in its finished dosage form that was
12
initially introduced into commerce prior to the initial
13
introduction into commerce of a controlled substance in its
14
finished dosage form which it may substantially resemble.
15

Nothing in this subsection (y) prohibits the dispensing or
16
distributing of noncontrolled substances by persons authorized
17
to dispense and distribute controlled substances under this
18
Act, provided that such action would be deemed to be carried
19
out in good faith under subsection (u) if the substances
20
involved were controlled substances.
21

Nothing in this subsection (y) or in this Act prohibits
22
the manufacture, preparation, propagation, compounding,
23
processing, packaging, advertising or distribution of a drug
24
or drugs by any person registered pursuant to Section 510 of
25
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
26

(y-1) "Mail-order pharmacy" means a pharmacy that is

SB3221
- 17 -
LRB104 20204 RLC 33655 b
1
located in a state of the United States that delivers,
2
dispenses or distributes, through the United States Postal
3
Service or other common carrier, to Illinois residents, any
4
substance which requires a prescription.
5

(z) "Manufacture" means the production, preparation,
6
propagation, compounding, conversion or processing of a
7
controlled substance other than methamphetamine, either
8
directly or indirectly, by extraction from substances of
9
natural origin, or independently by means of chemical
10
synthesis, or by a combination of extraction and chemical
11
synthesis, and includes any packaging or repackaging of the
12
substance or labeling of its container, except that this term
13
does not include:
14

(1) by an ultimate user, the preparation or
15

compounding of a controlled substance for his or her own
16

use;
17

(2) by a practitioner, or his or her authorized agent
18

under his or her supervision, the preparation,
19

compounding, packaging, or labeling of a controlled
20

substance:
21

(a) as an incident to his or her administering or
22

dispensing of a controlled substance in the course of
23

his or her professional practice; or
24

(b) as an incident to lawful research, teaching or
25

chemical analysis and not for sale; or
26

(3) the packaging, repackaging, or labeling of drugs

SB3221
- 18 -
LRB104 20204 RLC 33655 b
1

only to the extent permitted under the Illinois Drug Reuse
2

Opportunity Program Act.
3

(z-1) (Blank).
4

(z-5) "Medication shopping" means the conduct prohibited
5
under subsection (a) of Section 314.5 of this Act.
6

(z-10) "Mid-level practitioner" means (i) a physician
7
assistant who has been delegated authority to prescribe
8
through a written delegation of authority by a physician
9
licensed to practice medicine in all of its branches, in
10
accordance with Section 7.5 of the Physician Assistant
11
Practice Act of 1987, (ii) an advanced practice registered
12
nurse who has been delegated authority to prescribe through a
13
written delegation of authority by a physician licensed to
14
practice medicine in all of its branches or by a podiatric
15
physician, in accordance with Section 65-40 of the Nurse
16
Practice Act, (iii) an advanced practice registered nurse
17
certified as a nurse practitioner, nurse midwife, or clinical
18
nurse specialist who has been granted authority to prescribe
19
by a hospital affiliate in accordance with Section 65-45 of
20
the Nurse Practice Act, (iv) an animal euthanasia agency, or
21
(v) a prescribing psychologist.
22

(aa) "Narcotic drug" means any of the following, whether
23
produced directly or indirectly by extraction from substances
24
of vegetable origin, or independently by means of chemical
25
synthesis, or by a combination of extraction and chemical
26
synthesis:

SB3221
- 19 -
LRB104 20204 RLC 33655 b
1

(1) opium, opiates, derivatives of opium and opiates,
2

including their isomers, esters, ethers, salts, and salts
3

of isomers, esters, and ethers, whenever the existence of
4

such isomers, esters, ethers, and salts is possible within
5

the specific chemical designation; however the term
6

"narcotic drug" does not include the isoquinoline
7

alkaloids of opium;
8

(2) (blank);
9

(3) opium poppy and poppy straw;
10

(4) coca leaves, except coca leaves and extracts of
11

coca leaves from which substantially all of the cocaine
12

and ecgonine, and their isomers, derivatives and salts,
13

have been removed;
14

(5) cocaine, its salts, optical and geometric isomers,
15

and salts of isomers;
16

(6) ecgonine, its derivatives, their salts, isomers,
17

and salts of isomers;
18

(7) any compound, mixture, or preparation which
19

contains any quantity of any of the substances referred to
20

in subparagraphs (1) through (6).
21

(bb) "Nurse" means a registered nurse licensed under the
22
Nurse Practice Act.
23

(cc) (Blank).
24

(dd) "Opiate" means a drug derived from or related to
25
opium.
26

(ee) "Opium poppy" means the plant of the species Papaver

SB3221
- 20 -
LRB104 20204 RLC 33655 b
1
somniferum L., except its seeds.
2

(ee-5) "Oral dosage" means a tablet, capsule, elixir, or
3
solution or other liquid form of medication intended for
4
administration by mouth, but the term does not include a form
5
of medication intended for buccal, sublingual, or transmucosal
6
administration.
7

(ff) "Parole and Pardon Board" means the Parole and Pardon
8
Board of the State of Illinois or its successor agency.
9

(gg) "Person" means any individual, corporation,
10
mail-order pharmacy, government or governmental subdivision or
11
agency, business trust, estate, trust, partnership or
12
association, or any other entity.
13

(hh) "Pharmacist" means any person who holds a license or
14
certificate of registration as a registered pharmacist, a
15
local registered pharmacist or a registered assistant
16
pharmacist under the Pharmacy Practice Act.
17

(ii) "Pharmacy" means any store, ship or other place in
18
which pharmacy is authorized to be practiced under the
19
Pharmacy Practice Act.
20

(ii-5) "Pharmacy shopping" means the conduct prohibited
21
under subsection (b) of Section 314.5 of this Act.
22

(ii-10) "Physician" (except when the context otherwise
23
requires) means a person licensed to practice medicine in all
24
of its branches.
25

(jj) "Poppy straw" means all parts, except the seeds, of
26
the opium poppy, after mowing.

SB3221
- 21 -
LRB104 20204 RLC 33655 b
1

(kk) "Practitioner" means a physician licensed to practice
2
medicine in all its branches, dentist, optometrist, podiatric
3
physician, veterinarian, scientific investigator, pharmacist,
4
physician assistant, advanced practice registered nurse,
5
licensed practical nurse, registered nurse, emergency medical
6
services personnel, hospital, laboratory, or pharmacy, or
7
other person licensed, registered, or otherwise lawfully
8
permitted by the United States or this State to distribute,
9
dispense, conduct research with respect to, administer or use
10
in teaching or chemical analysis, a controlled substance in
11
the course of professional practice or research.
12

(ll) "Pre-printed prescription" means a written
13
prescription upon which the designated drug has been indicated
14
prior to the time of issuance; the term does not mean a written
15
prescription that is individually generated by machine or
16
computer in the prescriber's office.
17

(mm) "Prescriber" means a physician licensed to practice
18
medicine in all its branches, dentist, optometrist,
19
prescribing psychologist licensed under Section 4.2 of the
20
Clinical Psychologist Licensing Act with prescriptive
21
authority delegated under Section 4.3 of the Clinical
22
Psychologist Licensing Act, podiatric physician, or
23
veterinarian who issues a prescription, a physician assistant
24
who issues a prescription for a controlled substance in
25
accordance with Section 303.05, a written delegation, and a
26
written collaborative agreement required under Section 7.5 of

SB3221
- 22 -
LRB104 20204 RLC 33655 b
1
the Physician Assistant Practice Act of 1987, an advanced
2
practice registered nurse with prescriptive authority
3
delegated under Section 65-40 of the Nurse Practice Act and in
4
accordance with Section 303.05, a written delegation, and a
5
written collaborative agreement under Section 65-35 of the
6
Nurse Practice Act, an advanced practice registered nurse
7
certified as a nurse practitioner, nurse midwife, or clinical
8
nurse specialist who has been granted authority to prescribe
9
by a hospital affiliate in accordance with Section 65-45 of
10
the Nurse Practice Act and in accordance with Section 303.05,
11
or an advanced practice registered nurse certified as a nurse
12
practitioner, nurse midwife, or clinical nurse specialist who
13
has full practice authority pursuant to Section 65-43 of the
14
Nurse Practice Act.
15

(nn) "Prescription" means a written, facsimile, or oral
16
order, or an electronic order that complies with applicable
17
federal requirements, of a physician licensed to practice
18
medicine in all its branches, dentist, podiatric physician or
19
veterinarian for any controlled substance, of an optometrist
20
in accordance with Section 15.1 of the Illinois Optometric
21
Practice Act of 1987, of a prescribing psychologist licensed
22
under Section 4.2 of the Clinical Psychologist Licensing Act
23
with prescriptive authority delegated under Section 4.3 of the
24
Clinical Psychologist Licensing Act, of a physician assistant
25
for a controlled substance in accordance with Section 303.05,
26
a written delegation, and a written collaborative agreement

SB3221
- 23 -
LRB104 20204 RLC 33655 b
1
required under Section 7.5 of the Physician Assistant Practice
2
Act of 1987, of an advanced practice registered nurse with
3
prescriptive authority delegated under Section 65-40 of the
4
Nurse Practice Act who issues a prescription for a controlled
5
substance in accordance with Section 303.05, a written
6
delegation, and a written collaborative agreement under
7
Section 65-35 of the Nurse Practice Act, of an advanced
8
practice registered nurse certified as a nurse practitioner,
9
nurse midwife, or clinical nurse specialist who has been
10
granted authority to prescribe by a hospital affiliate in
11
accordance with Section 65-45 of the Nurse Practice Act and in
12
accordance with Section 303.05 when required by law, or of an
13
advanced practice registered nurse certified as a nurse
14
practitioner, nurse midwife, or clinical nurse specialist who
15
has full practice authority pursuant to Section 65-43 of the
16
Nurse Practice Act.
17

(nn-5) "Prescription Information Library" (PIL) means an
18
electronic library that contains reported controlled substance
19
data.
20

(nn-10) "Prescription Monitoring Program" (PMP) means the
21
entity that collects, tracks, and stores reported data on
22
controlled substances and select drugs pursuant to Section
23
316.
24

(oo) "Production" or "produce" means manufacture,
25
planting, cultivating, growing, or harvesting of a controlled
26
substance other than methamphetamine.

SB3221
- 24 -
LRB104 20204 RLC 33655 b
1

(pp) "Registrant" means every person who is required to
2
register under Section 302 of this Act.
3

(qq) "Registry number" means the number assigned to each
4
person authorized to handle controlled substances under the
5
laws of the United States and of this State.
6

(qq-5) "Secretary" means, as the context requires, either
7
the Secretary of the Department or the Secretary of the
8
Department of Financial and Professional Regulation, and the
9
Secretary's designated agents.
10

(rr) "State" includes the State of Illinois and any state,
11
district, commonwealth, territory, insular possession thereof,
12
and any area subject to the legal authority of the United
13
States of America.
14

(rr-5) "Stimulant" means any drug that (i) causes an
15
overall excitation of central nervous system functions, (ii)
16
causes impaired consciousness and awareness, and (iii) can be
17
habit-forming or lead to a substance use disorder, including,
18
but not limited to, amphetamines and their analogs,
19
methylphenidate and its analogs, cocaine, and phencyclidine
20
and its analogs.
21

(rr-10) "Synthetic drug" includes, but is not limited to,
22
any synthetic cannabinoids or piperazines or any synthetic
23
cathinones as provided for in Schedule I.
24

(ss) "Ultimate user" means a person who lawfully possesses
25
a controlled substance for his or her own use or for the use of
26
a member of his or her household or for administering to an

SB3221
- 25 -
LRB104 20204 RLC 33655 b
1
animal owned by him or her or by a member of his or her
2
household.
3
(Source: P.A. 102-389, eff. 1-1-22; 102-538, eff. 8-20-21;
4
102-813, eff. 5-13-22; 103-881, eff. 1-1-25
.)

5

(720 ILCS 570/204)

(from Ch. 56 1/2, par. 1204)
6

Sec. 204.
(a) The controlled substances listed in this
7
Section are included in Schedule I.
8

(b) Unless specifically excepted or unless listed in
9
another schedule, any of the following opiates, including
10
their isomers, esters, ethers, salts, and salts of isomers,
11
esters, and ethers, whenever the existence of such isomers,
12
esters, ethers and salts is possible within the specific
13
chemical designation:
14

(1) Acetylmethadol;
15

(1.1)
(Blank);

Acetyl-alpha-methylfentanyl
16

(N-[1-(1-methyl-2-phenethyl)-

17

4-piperidinyl]-N-phenylacetamide);
18

(2) Allylprodine;
19

(3) Alphacetylmethadol, except

20

levo-alphacetylmethadol (also known as levo-alpha-

21

acetylmethadol, levomethadyl acetate, or LAAM);
22

(4) Alphameprodine;
23

(5) Alphamethadol;
24

(6) Alpha-methylfentanyl

25

(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)

SB3221
- 26 -
LRB104 20204 RLC 33655 b
1

propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-

2

propanilido) piperidine;
3

(6.1)
(Blank);

Alpha-methylthiofentanyl

4

(N-[1-methyl-2-(2-thienyl)ethyl-

5

4-piperidinyl]-N-phenylpropanamide);
6

(7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
7

(7.1) PEPAP

8

(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
9

(8) Benzethidine;
10

(9) Betacetylmethadol;
11

(9.1)
(Blank);

Beta-hydroxyfentanyl

12

(N-[1-(2-hydroxy-2-phenethyl)-

13

4-piperidinyl]-N-phenylpropanamide);
14

(10) Betameprodine;
15

(11) Betamethadol;
16

(12) Betaprodine;
17

(12.1) Brorphine;

18

(13) Clonitazene;
19

(14) Dextromoramide;
20

(15) Diampromide;
21

(16) Diethylthiambutene;
22

(17) Difenoxin;
23

(18) Dimenoxadol;
24

(19) Dimepheptanol;
25

(20) Dimethylthiambutene;
26

(21) Dioxaphetylbutyrate;

SB3221
- 27 -
LRB104 20204 RLC 33655 b
1

(22) Dipipanone;
2

(23) Ethylmethylthiambutene;
3

(24) Etonitazene;
4

(25) Etoxeridine;
5

(25.1) Flunitazene;

6

(26) Furethidine;
7

(27) Hydroxpethidine;
8

(27.1) Isotonitazene;

9

(28) Ketobemidone;
10

(29) Levomoramide;
11

(30) Levophenacylmorphan;
12

(31)
(Blank);

3-Methylfentanyl

13

(N-[3-methyl-1-(2-phenylethyl)-

14

4-piperidyl]-N-phenylpropanamide);
15

(31.1)
(Blank);

3-Methylthiofentanyl

16

(N-[(3-methyl-1-(2-thienyl)ethyl-

17

4-piperidinyl]-N-phenylpropanamide);
18

(31.2) Metonitazene;

19

(32) Morpheridine;
20

(33) Noracymethadol;
21

(34) Norlevorphanol;
22

(35) Normethadone;
23

(36) Norpipanone;
24

(36.1)
(Blank);

Para-fluorofentanyl

25

(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-

26

4-piperidinyl]propanamide);

SB3221
- 28 -
LRB104 20204 RLC 33655 b
1

(37) Phenadoxone;
2

(38) Phenampromide;
3

(39) Phenomorphan;
4

(40) Phenoperidine;
5

(41) Piritramide;
6

(42) Proheptazine;
7

(43) Properidine;
8

(44) Propiram;
9

(45) Racemoramide;
10

(45.1)
(Blank);

Thiofentanyl

11

(N-phenyl-N-[1-(2-thienyl)ethyl-

12

4-piperidinyl]-propanamide);
13

(46) Tilidine;
14

(47) Trimeperidine;
15

(48)
(Blank);

Beta-hydroxy-3-methylfentanyl (other
16
name:

17

N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-

18

N-phenylpropanamide);
19

(49)
(Blank);

Furanyl fentanyl (FU-F);
20

(50)
(Blank);

Butyryl fentanyl;
21

(51)
(Blank);

Valeryl fentanyl;
22

(52)
(Blank);

Acetyl fentanyl;
23

(53)
(Blank);

Beta-hydroxy-thiofentanyl;

24

(54) 3,4-dichloro-N-[2-

25

(dimethylamino)cyclohexyl]-N-

26

methylbenzamide (U-47700);

SB3221
- 29 -
LRB104 20204 RLC 33655 b
1

(55) 4-chloro-N-[1-[2-

2

(4-nitrophenyl)ethyl]-2-piperidinylidene]-

3

benzenesulfonamide (W-18);
4

(56) 4-chloro-N-[1-(2-phenylethyl)

5

-2-piperidinylidene]-benzenesulfonamide (W-15);
6

(57)
(Blank).

acrylfentanyl (acryloylfentanyl).

7

(c) Unless specifically excepted or unless listed in
8
another schedule, any of the following opium derivatives, its
9
salts, isomers and salts of isomers, whenever the existence of
10
such salts, isomers and salts of isomers is possible within
11
the specific chemical designation:
12

(1) Acetorphine;
13

(2) Acetyldihydrocodeine;
14

(3) Benzylmorphine;
15

(4) Codeine methylbromide;
16

(5) Codeine-N-Oxide;
17

(6) Cyprenorphine;
18

(7) Desomorphine;
19

(8) Diacetyldihydromorphine (Dihydroheroin);
20

(9) Dihydromorphine;
21

(10) Drotebanol;
22

(11) Etorphine (except hydrochloride salt);
23

(12) Heroin;
24

(13) Hydromorphinol;
25

(14) Methyldesorphine;
26

(15) Methyldihydromorphine;

SB3221
- 30 -
LRB104 20204 RLC 33655 b
1

(16) Morphine methylbromide;
2

(17) Morphine methylsulfonate;
3

(18) Morphine-N-Oxide;
4

(19) Myrophine;
5

(20) Nicocodeine;
6

(21) Nicomorphine;
7

(22) Normorphine;
8

(23) Pholcodine;
9

(24) Thebacon.
10

(d) Unless specifically excepted or unless listed in
11
another schedule, any material, compound, mixture, or
12
preparation which contains any quantity of the following
13
hallucinogenic substances, or which contains any of its salts,
14
isomers and salts of isomers, whenever the existence of such
15
salts, isomers, and salts of isomers is possible within the
16
specific chemical designation (for the purposes of this
17
paragraph only, the term "isomer" includes the optical,
18
position and geometric isomers):
19

(1) 3,4-methylenedioxyamphetamine

20
(alpha-methyl,3,4-methylenedioxyphenethylamine,

21
methylenedioxyamphetamine, MDA);
22

(1.1) Alpha-ethyltryptamine
23

(some trade or other names: etryptamine;
24

MONASE; alpha-ethyl-1H-indole-3-ethanamine;
25

3-(2-aminobutyl)indole; a-ET; and AET);
26

(2) 3,4-methylenedioxymethamphetamine (MDMA);

SB3221
- 31 -
LRB104 20204 RLC 33655 b
1

(2.1) 3,4-methylenedioxy-N-ethylamphetamine

2
(also known as: N-ethyl-alpha-methyl-

3
3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,

4
and MDEA);
5

(2.2)
(Blank);

N-Benzylpiperazine (BZP);

6

(2.2-1)
(Blank);

Trifluoromethylphenylpiperazine
7

(TFMPP);

8

(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
9

(4) 3,4,5-trimethoxyamphetamine (TMA);
10

(5) (Blank);
11

(6) Diethyltryptamine (DET);
12

(7) Dimethyltryptamine (DMT);
13

(7.1) 5-Methoxy-diallyltryptamine;
14

(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
15

(9) Ibogaine (some trade and other names:

16

7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-

17

6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]

18

indole; Tabernanthe iboga);
19

(10) Lysergic acid diethylamide;
20

(10.1) Salvinorin A;
21

(10.5) Salvia divinorum (meaning all parts of the
22

plant presently classified botanically as Salvia
23

divinorum, whether growing or not, the seeds thereof, any
24

extract from any part of that plant, and every compound,
25

manufacture, salts, isomers, and salts of isomers whenever
26

the existence of such salts, isomers, and salts of isomers

SB3221
- 32 -
LRB104 20204 RLC 33655 b
1

is possible within the specific chemical designation,
2

derivative, mixture, or preparation of that plant, its
3

seeds or extracts);
4

(11) 3,4,5-trimethoxyphenethylamine (Mescaline);
5

(12) Peyote (meaning all parts of the plant presently
6

classified botanically as Lophophora williamsii Lemaire,
7

whether growing or not, the seeds thereof, any extract
8

from any part of that plant, and every compound,
9

manufacture, salts, derivative, mixture, or preparation of
10

that plant, its seeds or extracts);
11

(13) N-ethyl-3-piperidyl benzilate (JB 318);
12

(14) N-methyl-3-piperidyl benzilate;
13

(14.1) N-hydroxy-3,4-methylenedioxyamphetamine

14

(also known as N-hydroxy-alpha-methyl-

15

3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
16

(15) Parahexyl; some trade or other names:

17
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-

18
dibenzo (b,d) pyran; Synhexyl;
19

(16) Psilocybin;
20

(17) Psilocyn;
21

(18) Alpha-methyltryptamine (AMT);
22

(19) 2,5-dimethoxyamphetamine

23

(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
24

(20) 4-bromo-2,5-dimethoxyamphetamine

25

(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;

26

4-bromo-2,5-DMA);

SB3221
- 33 -
LRB104 20204 RLC 33655 b
1

(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

2
Some trade or other names: 2-(4-bromo-

3
2,5-dimethoxyphenyl)-1-aminoethane;

4
alpha-desmethyl DOB, 2CB, Nexus;
5

(21) 4-methoxyamphetamine

6

(4-methoxy-alpha-methylphenethylamine;

7

paramethoxyamphetamine; PMA);
8

(22) (Blank);
9

(23) Ethylamine analog of phencyclidine.

10
Some trade or other names:

11
N-ethyl-1-phenylcyclohexylamine,

12
(1-phenylcyclohexyl) ethylamine,

13
N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
14

(24) Pyrrolidine analog of phencyclidine. Some trade
15

or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
16

PHP;
17

(25) 5-methoxy-3,4-methylenedioxy-amphetamine;
18

(26) 2,5-dimethoxy-4-ethylamphetamine

19

(another name: DOET);
20

(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

21

(another name: TCPy);
22

(28) (Blank);
23

(29) Thiophene analog of phencyclidine (some trade

24
or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

25
2-thienyl analog of phencyclidine; TPCP; TCP);
26

(29.1) Benzothiophene analog of phencyclidine. Some

SB3221
- 34 -
LRB104 20204 RLC 33655 b
1

trade or other names: BTCP or benocyclidine;
2

(29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
3

(30) Bufotenine (some trade or other names:

4

3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

5

3-(2-dimethylaminoethyl)-5-indolol;

6

5-hydroxy-N,N-dimethyltryptamine;

7

N,N-dimethylserotonin; mappine);
8

(31) (Blank);
9

(32) (Blank);
10

(33) (Blank);
11

(34) (Blank);
12

(34.5) (Blank);
13

(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
14

(2-methyloctan-2-yl)-6a,7,
15

10,10a-tetrahydrobenzo[c]chromen-1-ol
16

Some trade or other names: HU-210;
17

(35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
18

dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
19

tetrahydrobenzo[c]chromen-1-ol, its isomers,
20

salts, and salts of isomers; Some trade or other
21

names: HU-210, Dexanabinol;
22

(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
23

6,6-dimethyl-3-(2-methyloctan-2-yl)-
24

6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
25

Some trade or other names: HU-211;
26

(37) (Blank);

SB3221
- 35 -
LRB104 20204 RLC 33655 b
1

(38) (Blank);
2

(39) (Blank);
3

(40) (Blank);
4

(41) (Blank);
5

(42)
(Blank);

Any compound structurally derived from
6

3-(1-naphthoyl)indole or
7

1H-indol-3-yl-(1-naphthyl)methane by substitution at the
8

nitrogen atom of the indole ring by alkyl, haloalkyl,
9

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
10

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
11

2-(4-morpholinyl)ethyl whether or not further substituted
12

in the indole ring to any extent, whether or not
13

substituted in the naphthyl ring to any extent. Examples
14

of this structural class include, but are not limited to,
15

JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
16

(43)
(Blank);

Any compound structurally derived from
17

3-(1-naphthoyl)pyrrole by substitution at the nitrogen
18

atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
19

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
20

halide, 1-(N-methyl-2-piperidinyl)methyl, or
21

2-(4-morpholinyl)ethyl, whether or not further substituted
22

in the pyrrole ring to any extent, whether or not
23

substituted in the naphthyl ring to any extent. Examples
24

of this structural class include, but are not limited to,
25

JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

26

(44)
(Blank);

Any compound structurally derived from

SB3221
- 36 -
LRB104 20204 RLC 33655 b
1

1-(1-naphthylmethyl)indene by substitution at the
2

3-position of the indene ring by alkyl, haloalkyl,
3

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
4

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
5

2-(4-morpholinyl)ethyl whether or not further substituted
6

in the indene ring to any extent, whether or not
7

substituted in the naphthyl ring to any extent. Examples
8

of this structural class include, but are not limited to,
9

JWH-176;

10

(45)
(Blank);

Any compound structurally derived from
11

3-phenylacetylindole by substitution at the nitrogen atom
12

of the indole ring with alkyl, haloalkyl, alkenyl,
13

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
14

halide, 1-(N-methyl-2-piperidinyl)methyl, or
15

2-(4-morpholinyl)ethyl, whether or not further substituted
16

in the indole ring to any extent, whether or not
17

substituted in the phenyl ring to any extent. Examples of
18

this structural class include, but are not limited to,
19

JWH-167, JWH-250, JWH-251, and RCS-8;

20

(46)
(Blank);

Any compound structurally derived from
21

2-(3-hydroxycyclohexyl)phenol by substitution at the
22

5-position of the phenolic ring by alkyl, haloalkyl,
23

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
24

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
25

2-(4-morpholinyl)ethyl, whether or not substituted in the
26

cyclohexyl ring to any extent. Examples of this structural

SB3221
- 37 -
LRB104 20204 RLC 33655 b
1

class include, but are not limited to, CP 47, 497 and its
2

C8 homologue (cannabicyclohexanol);

3

(46.1)
(Blank);

Any compound structurally derived from
4

3-(benzoyl) indole with substitution at the nitrogen atom
5

of the indole ring by an alkyl, haloalkyl, alkenyl,
6

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
7

halide, 1-(N-methyl-2-piperidinyl)methyl, or
8

2-(4-morpholinyl)ethyl group whether or not further
9

substituted in the indole ring to any extent and whether
10

or not substituted in the phenyl ring to any extent.
11

Examples of this structural class include, but are not
12

limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
13

48,098), and RCS-4;

14

(47) (Blank);
15

(48) (Blank);
16

(49) (Blank);
17

(50) (Blank);
18

(51) (Blank);
19

(52) (Blank);
20

(53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
21

Some trade or other names: 2C-T-7;
22

(53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
23

trade or other names: 2C-E;
24

(53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
25

trade or other names: 2C-D;
26

(53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some

SB3221
- 38 -
LRB104 20204 RLC 33655 b
1

trade or other names: 2C-C;
2

(53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
3

or other names: 2C-I;
4

(53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
5

trade or other names: 2C-T-2;
6

(53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
7

Some trade or other names: 2C-T-4;
8

(53.7) 2,5-dimethoxyphenethylamine. Some trade or
9

other names: 2C-H;
10

(53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
11

trade or other names: 2C-N;
12

(53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
13

trade or other names: 2C-P;
14

(53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
15

Some trade or other names: 2C-G;
16

(53.11) The N-(2-methoxybenzyl) derivative of any 2C
17

phenethylamine referred to in subparagraphs (20.1), (53),
18

(53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
19

(53.8), (53.9), and (53.10) including, but not limited to,
20

25I-NBOMe and 25C-NBOMe;
21

(54) 5-Methoxy-N,N-diisopropyltryptamine;
22

(55) (Blank);
23

(56) (Blank);
24

(57) (Blank);
25

(58) (Blank);
26

(59)
(Blank);

3-cyclopropoylindole with substitution

SB3221
- 39 -
LRB104 20204 RLC 33655 b
1

at the nitrogen atom of the indole ring by alkyl,
2

haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
3

aryl halide, alkyl aryl halide,
4

1-(N-methyl-2-piperidinyl)methyl, or
5

2-(4-morpholinyl)ethyl, whether or not further substituted
6

on the indole ring to any extent, whether or not
7

substituted on the cyclopropyl ring to any extent:
8

including, but not limited to, XLR11, UR144, FUB-144;

9

(60)
(Blank);

3-adamantoylindole with substitution at
10

the nitrogen atom of the indole ring by alkyl, haloalkyl,
11

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
12

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
13

2-(4-morpholinyl)ethyl, whether or not further substituted
14

on the indole ring to any extent, whether or not
15

substituted on the adamantyl ring to any extent:
16

including, but not limited to, AB-001;

17

(61)
(Blank);

N-(adamantyl)-indole-3-carboxamide with
18

substitution at the nitrogen atom of the indole ring by
19

alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
20

cycloalkylethyl, aryl halide, alkyl aryl halide,
21

1-(N-methyl-2-piperidinyl)methyl, or
22

2-(4-morpholinyl)ethyl, whether or not further substituted
23

on the indole ring to any extent, whether or not
24

substituted on the adamantyl ring to any extent:
25

including, but not limited to, APICA/2NE-1, STS-135;

26

(62)
(Blank);

N-(adamantyl)-indazole-3-carboxamide

SB3221
- 40 -
LRB104 20204 RLC 33655 b
1

with substitution at a nitrogen atom of the indazole ring
2

by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
3

cycloalkylethyl, aryl halide, alkyl aryl halide,
4

1-(N-methyl-2-piperidinyl)methyl, or
5

2-(4-morpholinyl)ethyl, whether or not further substituted
6

on the indazole ring to any extent, whether or not
7

substituted on the adamantyl ring to any extent:
8

including, but not limited to, AKB48, 5F-AKB48;

9

(63)
(Blank);

1H-indole-3-carboxylic acid
10

8-quinolinyl ester with substitution at the nitrogen atom
11

of the indole ring by alkyl, haloalkyl, alkenyl,
12

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
13

halide, 1-(N-methyl-2-piperidinyl)methyl, or
14

2-(4-morpholinyl)ethyl, whether or not further substituted
15

on the indole ring to any extent, whether or not
16

substituted on the quinoline ring to any extent:
17

including, but not limited to, PB22, 5F-PB22, FUB-PB-22;

18

(64)
(Blank);

3-(1-naphthoyl)indazole with
19

substitution at the nitrogen atom of the indazole ring by
20

alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
21

cycloalkylethyl, aryl halide, alkyl aryl halide,
22

1-(N-methyl-2-piperidinyl)methyl, or
23

2-(4-morpholinyl)ethyl, whether or not further substituted
24

on the indazole ring to any extent, whether or not
25

substituted on the naphthyl ring to any extent: including,
26

but not limited to, THJ-018, THJ-2201;

SB3221
- 41 -
LRB104 20204 RLC 33655 b
1

(65)
(Blank);

2-(1-naphthoyl)benzimidazole with
2

substitution at the nitrogen atom of the benzimidazole
3

ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
4

cycloalkylethyl, aryl halide, alkyl aryl halide,
5

1-(N-methyl-2-piperidinyl)methyl, or
6

2-(4-morpholinyl)ethyl, whether or not further substituted
7

on the benzimidazole ring to any extent, whether or not
8

substituted on the naphthyl ring to any extent: including,
9

but not limited to, FUBIMINA;

10

(66)
(Blank);

N-(1-amino-3-methyl-1-oxobutan-2-yl)-
11

1H-indazole-3-carboxamide with substitution on the
12

nitrogen atom of the indazole ring by alkyl, haloalkyl,
13

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
14

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
15

2-(4-morpholinyl)ethyl, whether or not further substituted
16

on the indazole ring to any extent: including, but not
17

limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

18

(67)
(Blank);

N-(1-amino-3,3-dimethyl-1-oxobutan-
19

2-yl)-1H-indazole-3-carboxamide with substitution on the
20

nitrogen atom of the indazole ring by alkyl, haloalkyl,
21

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
22

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
23

2-(4-morpholinyl)ethyl, whether or not further substituted
24

on the indazole ring to any extent: including, but not
25

limited to, ADB-PINACA, ADB-FUBINACA;

26

(68)
(Blank);

N-(1-amino-3,3-dimethyl-1-oxobutan-

SB3221
- 42 -
LRB104 20204 RLC 33655 b
1

2-yl)-1H-indole-3-carboxamide with substitution on the
2

nitrogen atom of the indole ring by alkyl, haloalkyl,
3

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
4

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
5

2-(4-morpholinyl)ethyl, whether or not further substituted
6

on the indole ring to any extent: including, but not
7

limited to, ADBICA, 5F-ADBICA;

8

(69)
(Blank);

N-(1-amino-3-methyl-1-oxobutan-2 -
9

yl)-1H-indole-3-carboxamide with substitution on the
10

nitrogen atom of the indole ring by alkyl, haloalkyl,
11

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
12

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
13

2-(4-morpholinyl)ethyl, whether or not further substituted
14

on the indole ring to any extent: including, but not
15

limited to, ABICA, 5F-ABICA;

16

(70)
(Blank);

Methyl 2-(1H-indazole-3-carboxamido)-3-
17

methylbutanoate with substitution on the nitrogen atom of
18

the indazole ring by alkyl, haloalkyl, alkenyl,
19

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
20

halide, 1-(N-methyl-2-piperidinyl)methyl, or
21

2-(4-morpholinyl)ethyl, whether or not further substituted
22

on the indazole ring to any extent: including, but not
23

limited to, AMB, 5F-AMB;

24

(71)
(Blank);

Methyl 2-(1H-indazole-3-carboxamido)-
25

3,3-dimethylbutanoate with substitution on the nitrogen
26

atom of the indazole ring by alkyl, haloalkyl, alkenyl,

SB3221
- 43 -
LRB104 20204 RLC 33655 b
1

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
2

halide, 1-(N-methyl-2-piperidinyl)methyl, or
3

2-(4-morpholinyl)ethyl, whether or not further substituted
4

on the indazole ring to any extent: including, but not
5

limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

6

(72)
(Blank);

Methyl 2-(1H-indole-3-carboxamido)-3-
7

methylbutanoate with substitution on the nitrogen atom of
8

the indole ring by alkyl, haloalkyl, alkenyl,
9

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
10

halide, 1-(N-methyl-2-piperidinyl)methyl, or
11

2-(4-morpholinyl)ethyl, whether or not further substituted
12

on the indazole ring to any extent: including, but not
13

limited to, MMB018, MMB2201, and AMB-CHMICA;

14

(73)
(Blank);

Methyl 2-(1H-indole-3-carboxamido)-3,3-
15

dimethylbutanoate with substitution on the nitrogen atom
16

of the indole ring by alkyl, haloalkyl, alkenyl,
17

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18

halide, 1-(N-methyl-2-piperidinyl)methyl, or
19

2-(4-morpholinyl)ethyl, whether or not further substituted
20

on the indazole ring to any extent: including, but not
21

limited to, MDMB-CHMICA;

22

(74)
(Blank);

N-(1-Amino-1-oxo-3-phenylpropan-
23

2-yl)-1H-indazole-3-carboxamide with substitution on the
24

nitrogen atom of the indazole ring by alkyl, haloalkyl,
25

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
26

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or

SB3221
- 44 -
LRB104 20204 RLC 33655 b
1

2-(4-morpholinyl)ethyl, whether or not further substituted
2

on the indazole ring to any

extent: including, but not
3

limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

4

(75)
(Blank);

N-(1-Amino-1-oxo-3-phenylpropan-
5

2-yl)-1H-indole-3-carboxamide with substitution on the
6

nitrogen atom of the indole ring by alkyl, haloalkyl,
7

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
8

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
9

2-(4-morpholinyl)ethyl, whether or not further substituted
10

on the indazole ring to any extent: including, but not
11

limited to, APP-PICA and 5-fluoro-APP-PICA;

12

(76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
13

4-AcO-DMT;
14

(77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
15

name 5-MeO-MIPT;
16

(78) 4-hydroxy Diethyltryptamine (4-HO-DET);
17

(79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
18

(80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
19

(81) 4-hydroxy-N-methyl-N-isopropyltryptamine
20

(4-HO-MiPT);
21

(82)
(Blank);

Fluorophenylpiperazine;
22

(83) Methoxetamine;
23

(84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
24

ethcathinone).
25

(e) Unless specifically excepted or unless listed in
26
another schedule, any material, compound, mixture, or

SB3221
- 45 -
LRB104 20204 RLC 33655 b
1
preparation which contains any quantity of the following
2
substances having a depressant effect on the central nervous
3
system, including its salts, isomers, and salts of isomers
4
whenever the existence of such salts, isomers, and salts of
5
isomers is possible within the specific chemical designation:
6

(1) mecloqualone;
7

(2) methaqualone; and
8

(3) gamma hydroxybutyric acid.
9

(f) Unless specifically excepted or unless listed in
10
another schedule, any material, compound, mixture, or
11
preparation which contains any quantity of the following
12
substances having a stimulant effect on the central nervous
13
system, including its salts, isomers, and salts of isomers:
14

(1) Fenethylline;
15

(2) N-ethylamphetamine;
16

(3) Aminorex (some other names:

17

2-amino-5-phenyl-2-oxazoline; aminoxaphen;

18

4-5-dihydro-5-phenyl-2-oxazolamine) and its

19

salts, optical isomers, and salts of optical isomers;
20

(4) Methcathinone (some other names:

21

2-methylamino-1-phenylpropan-1-one;

22

Ephedrone; 2-(methylamino)-propiophenone;

23

alpha-(methylamino)propiophenone; N-methylcathinone;

24

methycathinone; Monomethylpropion; UR 1431) and its

25

salts, optical isomers, and salts of optical isomers;
26

(5) Cathinone (some trade or other names:

SB3221
- 46 -
LRB104 20204 RLC 33655 b
1

2-aminopropiophenone; alpha-aminopropiophenone;

2

2-amino-1-phenyl-propanone; norephedrone);
3

(6) N,N-dimethylamphetamine (also known as:

4

N,N-alpha-trimethyl-benzeneethanamine;

5

N,N-alpha-trimethylphenethylamine);
6

(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-

7

4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
8

(8) 3,4-Methylenedioxypyrovalerone (MDPV);
9

(9) Halogenated amphetamines and

10

methamphetamines - any compound derived from either

11

amphetamine or methamphetamine through the substitution

12

of a halogen on the phenyl ring, including, but not

13

limited to, 2-fluoroamphetamine, 3-

14

fluoroamphetamine and 4-fluoroamphetamine;
15

(10) Aminopropylbenzofuran (APB):

16

including 4-(2-Aminopropyl) benzofuran, 5-

17

(2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)

18

benzofuran, and 7-(2-Aminopropyl) benzofuran;
19

(11) Aminopropyldihydrobenzofuran (APDB):

20

including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,

21

5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,

22

6-(2-Aminopropyl)-2,3-dihydrobenzofuran,

23

and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
24

(12) Methylaminopropylbenzofuran

25

(MAPB): including 4-(2-methylaminopropyl)

26

benzofuran, 5-(2-methylaminopropyl)benzofuran,

SB3221
- 47 -
LRB104 20204 RLC 33655 b
1

6-(2-methylaminopropyl)benzofuran

2

and 7-(2-methylaminopropyl)benzofuran
;

.

3

(13) Methylaminopropyldihydrobenzofuran

4

(MAPDB): including 1-(2,3-dihydrobenzofuran-5-yl)-

5

N-methylpropan-2-amine.

6

(g) Temporary listing of substances subject to emergency
7
scheduling. Any material, compound, mixture, or preparation
8
that contains any quantity of the following substances:
9

(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
10

(benzylfentanyl), its optical isomers, isomers, salts, and
11

salts of isomers;
12

(2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
13

phenylpropanamide (thenylfentanyl), its optical isomers,
14

salts, and salts of isomers.
15

(h) Synthetic cathinones. Unless specifically excepted,
16
any chemical compound which is not approved by the United
17
States Food and Drug Administration or, if approved, is not
18
dispensed or possessed in accordance with State or federal
19
law, not including bupropion, structurally derived from
20
2-aminopropan-1-one by substitution at the 1-position with
21
either phenyl, naphthyl, or thiophene ring systems, whether or
22
not the compound is further modified in one or more of the
23
following ways:
24

(1) by substitution in the ring system to any extent
25

with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
26

halide substituents, whether or not further substituted in

SB3221
- 48 -
LRB104 20204 RLC 33655 b
1

the ring system by one or more other univalent
2

substituents. Examples of this class include, but are not
3

limited to, 3,4-Methylenedioxycathinone (bk-MDA);
4

(2) by substitution at the 3-position with an acyclic
5

alkyl substituent. Examples of this class include, but are
6

not limited to, 2-methylamino-1-phenylbutan-1-one
7

(buphedrone); or
8

(3) by substitution at the 2-amino nitrogen atom with
9

alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
10

inclusion of the 2-amino nitrogen atom in a cyclic
11

structure. Examples of this class include, but are not
12

limited to, Dimethylcathinone, Ethcathinone, and
13

a-Pyrrolidinopropiophenone (a-PPP); or
14

Any other synthetic cathinone which is not approved by the
15
United States Food and Drug Administration or, if approved, is
16
not dispensed or possessed in accordance with State or federal
17
law.
18

(i) Synthetic cannabinoids or piperazines. Any synthetic
19
cannabinoid or piperazine which is not approved by the United
20
States Food and Drug Administration or, if approved, which is
21
not dispensed or possessed in accordance with State and
22
federal law.
23

(1) As used in this Section, "synthetic cannabinoid"
24

includes, but is not limited to, any compound, as
25

identified in a report from an accredited forensic
26

laboratory, that is structurally derived from any one or

SB3221
- 49 -
LRB104 20204 RLC 33655 b
1

more of the following compounds:
2

(A) Any compound structurally derived from
3

3-(1-naphthoyl)indole or
4

1H-indol-3-yl-(1-naphthyl)methane by substitution at
5

the nitrogen atom of the indole ring by alkyl,
6

haloalkyl, alkenyl, cycloalkylmethyl,
7

cycloalkylethyl, aryl halide, alkyl aryl halide,
8

1-(N-methyl-2-piperidinyl)methyl, or
9

2-(4-morpholinyl)ethyl whether or not further
10

substituted in the indole ring to any extent, whether
11

or not substituted in the naphthyl ring to any extent.
12

Examples of this structural class include, but are not
13

limited to, JWH-018, AM-2201, JWH-175, JWH-184, and
14

JWH-185;
15

(B) 3-(1-naphthoyl)pyrrole by substitution at the
16

nitrogen atom of the pyrrole ring by alkyl, haloalkyl,
17

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
18

halide, alkyl aryl halide,
19

1-(N-methyl-2-piperidinyl)methyl, or
20

2-(4-morpholinyl)ethyl, whether or not further
21

substituted in the pyrrole ring to any extent, whether
22

or not substituted in the naphthyl ring to any extent.
23

Examples of this structural class include, but are not
24

limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
25

JWH-368;
26

(C) 1-(1-naphthylmethyl)indene by substitution at

SB3221
- 50 -
LRB104 20204 RLC 33655 b
1

the 3-position of the indene ring by alkyl, haloalkyl,
2

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
3

halide, alkyl aryl halide,
4

1-(N-methyl-2-piperidinyl)methyl, or
5

2-(4-morpholinyl)ethyl whether or not further
6

substituted in the indene ring to any extent, whether
7

or not substituted in the naphthyl ring to any extent.
8

Examples of this structural class include, but are not
9

limited to, JWH-176;
10

(D) 3-phenylacetylindole by substitution at the
11

nitrogen atom of the indole ring with alkyl,
12

haloalkyl, alkenyl, cycloalkylmethyl,
13

cycloalkylethyl, aryl halide, alkyl aryl halide,
14

1-(N-methyl-2-piperidinyl)methyl, or
15

2-(4-morpholinyl)ethyl, whether or not further
16

substituted in the indole ring to any extent, whether
17

or not substituted in the phenyl ring to any extent.
18

Examples of this structural class include, but are not
19

limited to, JWH-167, JWH-250, JWH-251, and RCS-8;
20

(E) 2-(3-hydroxycyclohexyl)phenol by substitution
21

at the 5-position of the phenolic ring by alkyl,
22

haloalkyl, alkenyl, cycloalkylmethyl,
23

cycloalkylethyl, aryl halide, alkyl aryl halide,
24

1-(N-methyl-2-piperidinyl)methyl, or
25

2-(4-morpholinyl)ethyl, whether or not substituted in
26

the cyclohexyl ring to any extent. Examples of this

SB3221
- 51 -
LRB104 20204 RLC 33655 b
1

structural class include, but are not limited to, CP
2

47, 497 and its C8 homologue (cannabicyclohexanol);
3

(F) 3-(benzoyl) indole with substitution at the
4

nitrogen atom of the indole ring by an alkyl,
5

haloalkyl, alkenyl, cycloalkylmethyl,
6

cycloalkylethyl, aryl halide, alkyl aryl halide,
7

1-(N-methyl-2-piperidinyl)methyl, or
8

2-(4-morpholinyl)ethyl group whether or not further
9

substituted in the indole ring to any extent and
10

whether or not substituted in the phenyl ring to any
11

extent. Examples of this structural class include, but
12

are not limited to, AM-630, AM-2233, AM-694,
13

Pravadoline (WIN 48,098), and RCS-4;
14

(G) 3-cyclopropoylindole with substitution at the
15

nitrogen atom of the indole ring by alkyl, haloalkyl,
16

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
17

halide, alkyl aryl halide,
18

1-(N-methyl-2-piperidinyl)methyl, or
19

2-(4-morpholinyl)ethyl, whether or not further
20

substituted on the indole ring to any extent, whether
21

or not substituted on the cyclopropyl ring to any
22

extent, including, but not limited to, XLR11, UR144,
23

FUB-144;
24

(H) 3-adamantoylindole with substitution at the
25

nitrogen atom of the indole ring by alkyl, haloalkyl,
26

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl

SB3221
- 52 -
LRB104 20204 RLC 33655 b
1

halide, alkyl aryl halide,
2

1-(N-methyl-2-piperidinyl)methyl, or
3

2-(4-morpholinyl)ethyl, whether or not further
4

substituted on the indole ring to any extent, whether
5

or not substituted on the adamantyl ring to any
6

extent, including, but not limited to, AB-001;
7

(I) N-(adamantyl)-indole-3-carboxamide with
8

substitution at the nitrogen atom of the indole ring
9

by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
10

cycloalkylethyl, aryl halide, alkyl aryl halide,
11

1-(N-methyl-2-piperidinyl)methyl, or
12

2-(4-morpholinyl)ethyl, whether or not further
13

substituted on the indole ring to any extent, whether
14

or not substituted on the adamantyl ring to any
15

extent, including, but not limited to, APICA/2NE-1,
16

STS-135;
17

(J) N-(adamantyl)-indazole-3-carboxamide with
18

substitution at a nitrogen atom of the indazole ring
19

by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
20

cycloalkylethyl, aryl halide, alkyl aryl halide,
21

1-(N-methyl-2-piperidinyl)methyl, or
22

2-(4-morpholinyl)ethyl, whether or not further
23

substituted on the indazole ring to any extent,
24

whether or not substituted on the adamantyl ring to
25

any extent, including, but not limited to, AKB48,
26

5F-AKB48;

SB3221
- 53 -
LRB104 20204 RLC 33655 b
1

(K) 1H-indole-3-carboxylic acid 8-quinolinyl ester
2

with substitution at the nitrogen atom of the indole
3

ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
4

cycloalkylethyl, aryl halide, alkyl aryl halide,
5

1-(N-methyl-2-piperidinyl)methyl, or
6

2-(4-morpholinyl)ethyl, whether or not further
7

substituted on the indole ring to any extent, whether
8

or not substituted on the quinoline ring to any
9

extent, including, but not limited to, PB22, 5F-PB22,
10

FUB-PB-22;
11

(L) 3-(1-naphthoyl)indazole with substitution at
12

the nitrogen atom of the indazole ring by alkyl,
13

haloalkyl, alkenyl, cycloalkylmethyl,
14

cycloalkylethyl, aryl halide, alkyl aryl halide,
15

1-(N-methyl-2-piperidinyl)methyl, or
16

2-(4-morpholinyl)ethyl, whether or not further
17

substituted on the indazole ring to any extent,
18

whether or not substituted on the naphthyl ring to any
19

extent, including, but not limited to, THJ-018,
20

THJ-2201;
21

(M) 2-(1-naphthoyl)benzimidazole with
22

substitution at the nitrogen atom of the benzimidazole
23

ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
24

cycloalkylethyl, aryl halide, alkyl aryl halide,
25

1-(N-methyl-2-piperidinyl)methyl, or
26

2-(4-morpholinyl)ethyl, whether or not further

SB3221
- 54 -
LRB104 20204 RLC 33655 b
1

substituted on the benzimidazole ring to any extent,
2

whether or not substituted on the naphthyl ring to any
3

extent, including, but not limited to, FUBIMINA;
4

(N) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-
5

indazole-3-carboxamide with substitution on the
6

nitrogen atom of the indazole ring by alkyl,
7

haloalkyl, alkenyl, cycloalkylmethyl,
8

cycloalkylethyl, aryl halide, alkyl aryl halide,
9

1-(N-methyl-2-piperidinyl)methyl, or
10

2-(4-morpholinyl)ethyl, whether or not further
11

substituted on the indazole ring to any extent,
12

including, but not limited to, AB-PINACA, AB-FUBINACA,
13

AB-CHMINACA;
14

(O) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
15

1H-indazole-3-carboxamide with substitution on the
16

nitrogen atom of the indazole ring by alkyl,
17

haloalkyl, alkenyl, cycloalkylmethyl,
18

cycloalkylethyl, aryl halide, alkyl aryl halide,
19

1-(N-methyl-2-piperidinyl)methyl, or
20

2-(4-morpholinyl)ethyl, whether or not further
21

substituted on the indazole ring to any extent,
22

including, but not limited to, ADB-PINACA,
23

ADB-FUBINACA;
24

(P) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
25

1H-indole-3-carboxamide with substitution on the
26

nitrogen atom of the indole ring by alkyl, haloalkyl,

SB3221
- 55 -
LRB104 20204 RLC 33655 b
1

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
2

halide, alkyl aryl halide,
3

1-(N-methyl-2-piperidinyl)methyl, or
4

2-(4-morpholinyl)ethyl, whether or not further
5

substituted on the indole ring to any extent,
6

including, but not limited to, ADBICA, 5F-ADBICA;
7

(Q) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-
8

indole-3-carboxamide with substitution on the nitrogen
9

atom of the indole ring by alkyl, haloalkyl, alkenyl,
10

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
11

aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
12

2-(4-morpholinyl)ethyl, whether or not further
13

substituted on the indole ring to any extent,
14

including, but not limited to, ABICA, 5F-ABICA;
15

(R) Methyl 2-(1H-indazole-3-carboxamido)-
16

3-methylbutanoate with substitution on the nitrogen
17

atom of the indazole ring by alkyl, haloalkyl,
18

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
19

halide, alkyl aryl halide,
20

1-(N-methyl-2-piperidinyl)methyl, or
21

2-(4-morpholinyl)ethyl, whether or not further
22

substituted on the indazole ring to any extent,
23

including, but not limited to, AMB, 5F-AMB;
24

(S) Methyl 2-(1H-indazole-3-carboxamido)-
25

3,3-dimethylbutanoate with substitution on the
26

nitrogen atom of the indazole ring by alkyl,

SB3221
- 56 -
LRB104 20204 RLC 33655 b
1

haloalkyl, alkenyl, cycloalkylmethyl,
2

cycloalkylethyl, aryl halide, alkyl aryl halide,
3

1-(N-methyl-2-piperidinyl)methyl, or
4

2-(4-morpholinyl)ethyl, whether or not further
5

substituted on the indazole ring to any extent,
6

including, but not limited to, 5-fluoro-MDMB-PINACA,
7

MDMB-FUBINACA;
8

(T) Methyl 2-(1H-indole-3-carboxamido)-3-
9

methylbutanoate with substitution on the nitrogen atom
10

of the indole ring by alkyl, haloalkyl, alkenyl,
11

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
12

aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
13

2-(4-morpholinyl)ethyl, whether or not further
14

substituted on the indole ring to any extent,
15

including, but not limited to, MMB018, MMB2201, and
16

AMB-CHMICA;
17

(U) Methyl 2-(1H-indole-3-carboxamido)-3,3-
18

dimethylbutanoate with substitution on the nitrogen
19

atom of the indole ring by alkyl, haloalkyl, alkenyl,
20

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
21

aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
22

2-(4-morpholinyl)ethyl, whether or not further
23

substituted on the indazole indole ring to any extent,
24

including, but not limited to, MDMB-CHMICA;
25

(V) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
26

indazole-3-carboxamide with substitution on the

SB3221
- 57 -
LRB104 20204 RLC 33655 b
1

nitrogen atom of the indazole ring by alkyl,
2

haloalkyl, alkenyl, cycloalkylmethyl,
3

cycloalkylethyl, aryl halide, alkyl aryl halide,
4

1-(N-methyl-2-piperidinyl)methyl, or
5

2-(4-morpholinyl)ethyl, whether or not further
6

substituted on the indazole ring to any extent,
7

including, but not limited to, APP-CHMINACA,
8

5-fluoro-APP-PINACA;
9

(W) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-
10

1H-indole-3-carboxamide with substitution on the
11

nitrogen atom of the indole ring by alkyl, haloalkyl,
12

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
13

halide, alkyl aryl halide,
14

1-(N-methyl-2-piperidinyl)methyl, or
15

2-(4-morpholinyl)ethyl, whether or not further
16

substituted on the indole ring to any extent,
17

including, but not limited to, APP-PICA and
18

5-fluoro-APP-PICA;
19

(X) 1H-indazole-3-carboxylic acid 8-quinolinyl
20

ester with substitution at the nitrogen atom of the
21

indazole ring by alkyl, haloalkyl, alkenyl,
22

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
23

aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
24

2-(4-morpholinyl)ethyl, whether or not further
25

substituted on the inazdole ring to any extent,
26

whether or not substituted on the quinoline ring to

SB3221
- 58 -
LRB104 20204 RLC 33655 b
1

any extent, including, but not limited to, SDB-005,
2

5-F-SDB-005;
3

(2) As used in this Section, "synthetic piperazine"
4

includes, but is not limited to, any of the following
5

compounds and their positional isomers:
6

(A) N-Benzylpiperazine (BZP);
7

(B) Trifluoromethylphenylpiperazine (TFMPP);
8

(C) Fluorophenylpiperazine;
9

(D) Chlorophenylpiperazine.

10

(j) Unless specifically excepted or listed in another
11
schedule, any chemical compound which is not approved by the
12
United States Food and Drug Administration or, if approved, is
13
not dispensed or possessed in accordance with State or federal
14
law, and is derived from the following structural classes and
15
their salts:
16

(1) Benzodiazepine class: A fused 1,4-diazepine and
17

benzene ring structure with a phenyl connected to the
18

1,4-diazepine ring, with any substitution(s) or
19

replacement(s) on the 1,4-diazepine or benzene ring, any
20

substitution(s) on the phenyl ring, or any combination
21

thereof. Examples of this class include but are not
22

limited to: Clonazolam, Flualprazolam; or
23

(2) Thienodiazepine class: A fused 1,4-diazepine and
24

thiophene ring structure with a phenyl connected to the
25

1,4-diazepine ring, with any substitution(s) or
26

replacement(s) on the 1,4-diazepine or thiophene ring, any

SB3221
- 59 -
LRB104 20204 RLC 33655 b
1

substitution(s) on the phenyl ring, or any combination
2

thereof. Examples of this class include but are not
3

limited to: Etizolam.
4

(k) Fentanyl-related substances.
5

(1) As used in this Section, "fentanyl-related
6

substance" means any compound, as identified in a report
7

from an accredited forensic laboratory, unless
8

specifically excepted or listed under another schedule,
9

that is not approved by the United States Food and Drug
10

Administration or, if approved, is not dispensed or
11

possessed in accordance with State or federal law and that
12

is structurally derived from fentanyl
13

(N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)-
14

propanamide) by one or more of the following
15

modifications:
16

(A) replacement of the phenyl portion of the
17

phenethyl group by any monocycle, whether or not
18

further substituted in or on the monocycle;
19

(B) substitution in or on the phenethyl group with
20

alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl,
21

amino, or nitro groups;
22

(C) substitution in or on the piperidine ring with
23

alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo,
24

haloalkyl, amino, or nitro groups;
25

(D) replacement of the aniline ring with any
26

aromatic monocycle whether or not further substituted

SB3221
- 60 -
LRB104 20204 RLC 33655 b
1

in or on the aromatic monocycle; or
2

(E) replacement of the N-propionyl group by
3

another acyl group.
4

(2) "Fentanyl-related substance" includes, but is not
5

limited to, the following substances:
6

(A) Acetyl-alpha-methylfentanyl;
7

(B) Alpha-methylfentanyl (N-(1-alpha-methyl-beta-
8

phenyl)ethyl-4-piperidyl) propionanilide;
9

1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
10

piperidine;
11

(C) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
12

thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
13

(D) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-
14

phenethyl)-4-piperidinyl]-N-phenylpropanamide
15

(E) 3-Methylfentanyl (N-[3-methyl-1-(2-
16

phenylethyl)-4-piperidyl]-N-phenylpropanamide);
17

(F) 3-Methylthiofentanyl (N-[(3-methyl-1-
18

(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
19

(G) Para-fluorofentanyl (N-(4-fluorophenyl)-
20

N-[1-(2-phenethyl)-4-piperidinyl]propanamide);
21

(H) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-
22

4-piperidinyl]-propanamide);
23

(I) Beta-hydroxy-3-methylfentanyl (other name:
24

N-[1-(2-hydroxy-2-phenethyl)-3-methyl-
25

4-piperidinyl]-N-phenylpropanamide);
26

(J) Furanyl fentanyl (FU-F);

SB3221
- 61 -
LRB104 20204 RLC 33655 b
1

(K) Butyryl fentanyl;
2

(L) Valeryl fentanyl;
3

(M) Acetyl fentanyl;
4

(N) Beta-hydroxy-thiofentanyl;
5

(O) Acrylfentanyl (acryloylfentanyl);
6

(P) Cyclopropyl fentanyl;
7

(Q) Crotonyl fentanyl;
8

(R) Methoxyacetyl fentanyl;
9

(S) Pentanoyl fentanyl;
10

(T) Cyclopentyl fentanyl;
11

(U) Isobutyryl fentanyl;
12

(V) Benzodioxolefentanyl;
13

(W) Tetrahydrofuran fentanyl.

14
(Source: P.A. 103-245, eff. 1-1-24
.)

15

(720 ILCS 570/206)

(from Ch. 56 1/2, par. 1206)
16

Sec. 206.
(a) The controlled substances listed in this
17
Section are included in Schedule II.
18

(b) Unless specifically excepted or unless listed in
19
another schedule, any of the following substances whether
20
produced directly or indirectly by extraction from substances
21
of vegetable origin, or independently by means of chemical
22
synthesis, or by combination of extraction and chemical
23
synthesis:
24

(1) Opium and opiates, and any salt, compound,
25

derivative or preparation of opium or opiate, excluding

SB3221
- 62 -
LRB104 20204 RLC 33655 b
1

apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
2

nalmefene, naloxone, and naltrexone, and their respective
3

salts, but including the following:
4

(i) Raw Opium;
5

(ii) Opium extracts;
6

(iii) Opium fluid extracts;
7

(iv) Powdered opium;
8

(v) Granulated opium;
9

(vi) Tincture of opium;
10

(vii) Codeine;
11

(viii) Ethylmorphine;
12

(ix) Etorphine Hydrochloride;
13

(x) Hydrocodone;
14

(xi) Hydromorphone;
15

(xii) Metopon;
16

(xiii) Morphine;
17

(xiii.5) 6-Monoacetylmorphine;
18

(xiv) Oxycodone;
19

(xv) Oxymorphone;
20

(xv.5) Tapentadol;
21

(xvi) Thebaine;
22

(xvii) Thebaine-derived butorphanol.
23

(xviii) Methorphan, except drug products
24

containing dextromethorphan that may be dispensed
25

pursuant to a prescription order of a practitioner and
26

are sold in compliance with the safety and labeling

SB3221
- 63 -
LRB104 20204 RLC 33655 b
1

standards as set forth by the United States Food and
2

Drug Administration, or drug products containing
3

dextromethorphan that are sold in solid, tablet,
4

liquid, capsule, powder, thin film, or gel form and
5

which are formulated, packaged, and sold in dosages
6

and concentrations for use as an over-the-counter drug
7

product. For the purposes of this Section,
8

"over-the-counter drug product" means a drug that is
9

available to consumers without a prescription and sold
10

in compliance with the safety and labeling standards
11

as set forth by the United States Food and Drug
12

Administration.
13

(2) Any salt, compound, isomer, derivative or
14

preparation thereof which is chemically equivalent or
15

identical with any of the substances referred to in
16

subparagraph (1), but not including the isoquinoline
17

alkaloids of opium;
18

(3) Opium poppy and poppy straw;
19

(4) Coca leaves and any salt, compound, isomer, salt
20

of an isomer, derivative, or preparation of coca leaves
21

including cocaine or ecgonine, and any salt, compound,
22

isomer, derivative, or preparation thereof which is
23

chemically equivalent or identical with any of these
24

substances, but not including decocainized coca leaves or
25

extractions of coca leaves which do not contain cocaine or
26

ecgonine (for the purpose of this paragraph, the term

SB3221
- 64 -
LRB104 20204 RLC 33655 b
1

"isomer" includes optical
, positional
and geometric
2

isomers);
3

(5) Concentrate of poppy straw (the crude extract of
4

poppy straw in either liquid, solid or powder form which
5

contains the phenanthrine alkaloids of the opium poppy).
6

(c) Unless specifically excepted or unless listed in
7
another schedule any of the following opiates, including their
8
isomers, esters, ethers, salts, and salts of isomers, whenever
9
the existence of these isomers, esters, ethers and salts is
10
possible within the specific chemical designation, dextrorphan
11
excepted:
12

(1) Alfentanil;
13

(1.1) Carfentanil;
14

(1.2) Thiafentanyl;
15

(2) Alphaprodine;
16

(3) Anileridine;
17

(4) Bezitramide;
18

(5) Bulk Dextropropoxyphene (non-dosage forms);
19

(6) Dihydrocodeine;
20

(7) Diphenoxylate;
21

(8) Fentanyl;
22

(9) Sufentanil;
23

(9.5) Remifentanil;
24

(10) Isomethadone;
25

(11) (Blank);
26

(12) Levorphanol (Levorphan);

SB3221
- 65 -
LRB104 20204 RLC 33655 b
1

(13) Metazocine;
2

(14) Methadone;
3

(15) Methadone-Intermediate,

4

4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
5

(16) Moramide-Intermediate,

6

2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic

7

acid;
8

(17) Pethidine (meperidine);
9

(18) Pethidine-Intermediate-A,

10

4-cyano-1-methyl-4-phenylpiperidine;
11

(19) Pethidine-Intermediate-B,

12

ethyl-4-phenylpiperidine-4-carboxylate;
13

(20) Pethidine-Intermediate-C,

14

1-methyl-4-phenylpiperidine-4-carboxylic acid;
15

(21) Phenazocine;
16

(22) Piminodine;
17

(23) Racemethorphan;
18

(24) (Blank);
19

(25) Levo-alphacetylmethadol (some other names:
20

levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
21

(d) Unless specifically excepted or unless listed in
22
another schedule, any material, compound, mixture, or
23
preparation which contains any quantity of the following
24
substances having a stimulant effect on the central nervous
25
system:
26

(1) Amphetamine, its salts, optical isomers, and salts

SB3221
- 66 -
LRB104 20204 RLC 33655 b
1

of its optical isomers;
2

(2) Methamphetamine, its salts, isomers, and salts of
3

its isomers;
4

(3) Phenmetrazine and its salts;
5

(4) Methylphenidate;
6

(5) Lisdexamfetamine.
7

(e) Unless specifically excepted or unless listed in
8
another schedule, any material, compound, mixture, or
9
preparation which contains any quantity of the following
10
substances having a depressant effect on the central nervous
11
system, including its salts, isomers, and salts of isomers
12
whenever the existence of such salts, isomers, and salts of
13
isomers is possible within the specific chemical designation:
14

(1) Amobarbital;
15

(2) Secobarbital;
16

(3) Pentobarbital;
17

(4) Pentazocine;
18

(5) Phencyclidine;
19

(6) Gluthethimide;
20

(7) (Blank).
21

(f) Unless specifically excepted or unless listed in
22
another schedule, any material, compound, mixture, or
23
preparation which contains any quantity of the following
24
substances:
25

(1) Immediate precursor to amphetamine and
26

methamphetamine:

SB3221
- 67 -
LRB104 20204 RLC 33655 b
1

(i) Phenylacetone
2

Some trade or other names: phenyl-2-propanone;
3

P2P; benzyl methyl ketone; methyl benzyl ketone.
4

(2) Immediate precursors to phencyclidine:
5

(i) 1-phenylcyclohexylamine;
6

(ii) 1-piperidinocyclohexanecarbonitrile (PCC).
7

(3) Nabilone.
8
(Source: P.A. 100-368, eff. 1-1-18
.)

9

(720 ILCS 570/208)

(from Ch. 56 1/2, par. 1208)
10

Sec. 208.
(a) The controlled substances listed in this
11
Section are included in Schedule III.
12

(b) Unless specifically excepted or unless listed in
13
another schedule, any material, compound, mixture, or
14
preparation which contains any quantity of the following
15
substances having a stimulant effect on the central nervous
16
system, including its salts, isomers (whether optical
17
position, or geometric), and salts of such isomers whenever
18
the existence of such salts, isomers, and salts of isomers is
19
possible within the specific chemical designation;
20

(1) Those compounds, mixtures, or preparations in
21

dosage unit form containing any stimulant substances
22

listed in Schedule II which compounds, mixtures, or
23

preparations were listed on August 25, 1971, as excepted
24

compounds under Title 21, Code of Federal Regulations,
25

Section 308.32, and any other drug of the quantitative

SB3221
- 68 -
LRB104 20204 RLC 33655 b
1

composition shown in that list for those drugs or which is
2

the same except that it contains a lesser quantity of
3

controlled substances;
4

(2) Benzphetamine;
5

(3) Chlorphentermine;
6

(4) Clortermine;
7

(5) Phendimetrazine.
8

(c) Unless specifically excepted or unless listed in
9
another schedule, any material, compound, mixture, or
10
preparation which contains any quantity of the following
11
substances having a potential for misuse associated with a
12
depressant effect on the central nervous system:
13

(1) Any compound, mixture, or preparation containing
14

amobarbital, secobarbital, pentobarbital or any salt
15

thereof and one or more other active medicinal ingredients
16

which are not listed in any schedule;
17

(2) Any suppository dosage form containing
18

amobarbital, secobarbital, pentobarbital or any salt of
19

any of these drugs and approved by the Federal Food and
20

Drug Administration for marketing only as a suppository;
21

(3) Any substance which contains any quantity of a
22

derivative of barbituric acid, or any salt thereof:
23

(3.1) Aprobarbital;
24

(3.2) Butabarbital (secbutabarbital);
25

(3.3) Butalbital;
26

(3.4) Butobarbital (butethal);

SB3221
- 69 -
LRB104 20204 RLC 33655 b
1

(4) Chlorhexadol;
2

(5) Methyprylon;
3

(6) Sulfondiethylmethane;
4

(7) Sulfonethylmethane;
5

(8) Sulfonmethane;
6

(9) Lysergic acid;
7

(10) Lysergic acid amide;
8

(10.1) Tiletamine or zolazepam or both, or any salt of
9

either of them.
10

Some trade or other names for a tiletamine-zolazepam

11

combination product: Telazol.

12

Some trade or other names for Tiletamine:

13

2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

14

Some trade or other names for zolazepam:

15

4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-

16

[3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
17

(11) Any material, compound, mixture or preparation
18

containing not more than 12.5 milligrams of pentazocine or
19

any of its salts, per 325 milligrams of aspirin;
20

(12) Any material, compound, mixture or preparation
21

containing not more than 12.5 milligrams of pentazocine or
22

any of its salts, per 325 milligrams of acetaminophen;
23

(13) Any material, compound, mixture or preparation
24

containing not more than 50 milligrams of pentazocine or
25

any of its salts plus naloxone HCl USP 0.5 milligrams, per
26

dosage unit;

SB3221
- 70 -
LRB104 20204 RLC 33655 b
1

(14) Ketamine;
2

(15) Thiopental
;

.

3

(16) Xylazine.

4

(d) Nalorphine.
5

(d.5) Buprenorphine.
6

(e) Unless specifically excepted or unless listed in
7
another schedule, any material, compound, mixture, or
8
preparation containing limited quantities of any of the
9
following narcotic drugs, or their salts calculated as the
10
free anhydrous base or alkaloid, as set forth below:
11

(1) not more than 1.8 grams of codeine per 100
12

milliliters or not more than 90 milligrams per dosage
13

unit, with an equal or greater quantity of an isoquinoline
14

alkaloid of opium;
15

(2) not more than 1.8 grams of codeine per 100
16

milliliters or not more than 90 milligrams per dosage
17

unit, with one or more active non-narcotic ingredients in
18

recognized therapeutic amounts;
19

(3) (blank);
20

(4) (blank);
21

(5) not more than 1.8 grams of dihydrocodeine per 100
22

milliliters or not more than 90 milligrams per dosage
23

unit, with one or more active, non-narcotic ingredients in
24

recognized therapeutic amounts;
25

(6) not more than 300 milligrams of ethylmorphine per
26

100 milliliters or not more than 15 milligrams per dosage

SB3221
- 71 -
LRB104 20204 RLC 33655 b
1

unit, with one or more active, non-narcotic ingredients in
2

recognized therapeutic amounts;
3

(7) not more than 500 milligrams of opium per 100
4

milliliters or per 100 grams, or not more than 25
5

milligrams per dosage unit, with one or more active,
6

non-narcotic ingredients in recognized therapeutic
7

amounts;
8

(8) not more than 50 milligrams of morphine per 100
9

milliliters or per 100 grams with one or more active,
10

non-narcotic ingredients in recognized therapeutic
11

amounts.
12

(f) Anabolic steroids, except the following anabolic
13
steroids that are exempt:
14

(1) Androgyn L.A.;
15

(2) Andro-Estro 90-4;
16

(3) depANDROGYN;
17

(4) DEPO-T.E.;
18

(5) depTESTROGEN;
19

(6) Duomone;
20

(7) DURATESTRIN;
21

(8) DUO-SPAN II;
22

(9) Estratest;
23

(10) Estratest H.S.;
24

(11) PAN ESTRA TEST;
25

(12) Premarin with Methyltestosterone;
26

(13) TEST-ESTRO Cypionates;

SB3221
- 72 -
LRB104 20204 RLC 33655 b
1

(14) Testosterone Cyp 50 Estradiol Cyp 2;
2

(15) Testosterone Cypionate-Estradiol Cypionate
3

injection; and
4

(16) Testosterone Enanthate-Estradiol Valerate
5

injection.
6

(g) Hallucinogenic substances.
7

(1) Dronabinol (synthetic) in sesame oil and
8

encapsulated in a soft gelatin capsule in a U.S. Food and
9

Drug Administration approved product. Some other names for
10

dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
11

6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
12

(-)-delta-9-(trans)-tetrahydrocannabinol.
13

(2) (Reserved).
14

(h) The Department may except by rule any compound,
15
mixture, or preparation containing any stimulant or depressant
16
substance listed in subsection (b) from the application of all
17
or any part of this Act if the compound, mixture, or
18
preparation contains one or more active medicinal ingredients
19
not having a stimulant or depressant effect on the central
20
nervous system, and if the admixtures are included therein in
21
combinations, quantity, proportion, or concentration that
22
vitiate the potential for misuse of the substances which have
23
a stimulant or depressant effect on the central nervous
24
system.
25
(Source: P.A. 103-881, eff. 1-1-25
.)

SB3221
- 73 -
LRB104 20204 RLC 33655 b
1

(720 ILCS 570/309.1 new)
2

Sec. 309.1.
Xylazine exemptions.
Notwithstanding the
3
scheduling of xylazine as a Schedule III controlled substance,
4
xylazine shall not be considered a controlled substance when:
5

(1) used by licensed Illinois veterinarians dispensing
6

or prescribing for, or administering to, a nonhuman
7

species of a drug containing xylazine that has been
8

approved by the U.S. Food and Drug Administration;
9

(2) used by licensed Illinois veterinarians dispensing
10

or prescribing for, or administering to, a nonhuman
11

species that is permissible under the Federal Food, Drug,
12

and Cosmetic Act;
13

(3) manufactured, distributed, or used as an active
14

pharmaceutical ingredient for manufacturing an animal drug
15

approved under the Federal Food, Drug, and Cosmetic Act;
16

(4) used by a licensed certified euthanasia technician
17

employed by a certified euthanasia agency; or
18

(5) used by a wildlife biologist engaged in legal or
19

authorized fieldwork under the indirect supervision of a
20

veterinarian.

21

Section 99.
Effective date.
This Act takes effect January
22
1, 2027.

Footer

Disclaimer

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.

Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.
Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn